Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Why Exelixis Jumped 10% in September

TheMotleyFool

0 0

Shares of Exelixis (NASDAQ: EXEL) rose 10% in September, according to data from S&P Global Market Intelligence, after the company announced a series of positive developments throughout the month related to various cancer therapies.

Exelixis is already on track to generate $1 billion in annual sales in 2021 through its primary drug Cabometyx, which is approved to treat first- and second-line renal cell carcinoma as well as advanced hepatocellular carcinoma.

Image source: Getty Images.

Source Fool.com

Like: 0

EXEL

Share